The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.

Biotech Halozyme Therapeutics believes the new version of Merck's blockbuster cancer drug Keytruda infringes on its patents, ...

New research in mice may explain why aspirin seems to lower the risk of people's cancers spreading out of control.

Dr. Jie Yang, who carried out the researchm described the drug as a less expensive solution that is more accessible globally.

Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...

Cancer cells have an insatiable appetite for energy as they multiply more rapidly than normal cells. Greedy cancer cells ...

A new drug that works against the main types of primary bone cancer has been developed by researchers at the University of ...

Half of all pancreatic-cancer patients live less than a year after diagnosis. But researchers say there is potential for ...

Can a drug that's used to treat malaria be repurposed to fight cancer? Researchers at The University of Texas at El Paso have ...

An experimental medicine from Protagonist Therapeutics stabilized red blood cells and improved symptoms in patients with a ...

Life science firm Nuvation Bio raised $250 million to bring its novel lung cancer therapy to market and help it reach ...

Halozyme Therapeutics claims Merck's new Keytruda version infringes on patents, requiring a licensing agreement, reports WSJ.